John C Ashton,Erin D Milligan
John C Ashton
Neuropathic pain is a worldwide epidemic that occurs in 3 to 8% of individuals in industrialized countries and is often refractory to existing treatments. Drugs currently available to target neuropathic pain are, at best, moderately effecti...
Lauren A Stahl,Denovan P Begg,Richard S Weisinger et al.
Lauren A Stahl et al.
Research has established that docosahexaenoic acid (DHA), a long-chain omega-3 polyunsaturated fatty acid (PUFA), plays a fundamental role in brain structure and function. Epidemiological and cross-sectional studies have also identified a r...
Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction [0.03%]
选择性烟碱型乙酰胆碱受体激动剂：具有认知障碍的神经精神疾病的潜在治疗方法
Stephaine L Cincotta,Matthew S Yorek,Travis M Moschak et al.
Stephaine L Cincotta et al.
Cognitive impairment is one of the most functionally debilitating aspects of neuropsychiatric and neurodegenerative disorders, such as schizophrenia and Alzheimer's disease, despite treatment with available pharmacotherapies. There is emerg...
Sham S Nikam,Alok K Awasthi
Sham S Nikam
Many of the drugs currently marketed for the treatment of schizophrenia are dopamine D2 receptor antagonists or partial agonists with or without mixed receptor pharmacology, and primarily treat the positive symptoms of schizophrenia. These ...
Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges [0.03%]
多靶点及单靶点药物治疗重大精神疾病：机遇与挑战
Erik H F Wong,Sham S Nikam,Mohammed Shahid
Erik H F Wong
There is growing pressure to find more effective therapies for major psychiatric disorders, such as schizophrenia and depressive disorder. The repeated disappointments that have been experienced with highly selective, single-target agents h...
Perseverance furthers? The role of the drug hunter in the postgenomic era [0.03%]
坚持下去就会有收获吗？基因组时代之后的药物猎人的角色
Michael Williams
Michael Williams
MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer [0.03%]
用于治疗上皮性卵巢癌的针对叶酸受体α的全人源单克隆抗体MORAb-003
Kimberly R Kalli
Kimberly R Kalli
Morphotek Inc is developing MORAb-003, a humanized monoclonal antibody directed against folate receptor alpha, for the potential treatment of ovarian cancer. Phase II clinical trialsof MORAb-003, either alone or in combination with platinum...
Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer [0.03%]
厄洛替尼，一种海兔化合物Halichondrin B的筒状抑制剂的简化类似物，用于癌症治疗研究
Simon Newman
Simon Newman
Eisai Co Ltd is developing eribulin, a simplified synthetic macrocyclic ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Phase III trials are underway in the US and Europe for patients with breas...
Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer [0.03%]
临床聚腺苷二磷酸核糖聚合酶抑制剂的癌症治疗方法
Cristina Lewis,Jennifer A Low
Cristina Lewis
Poly(ADP-ribose) polymerase (PARP) is believed to play a critical role in the detection of DNA damage and initiation of DNA repair. Although inhibition of PARP has received increasing attention for therapeutic application in a wide variety ...
Archana Monie,Chien-Fu Hung,T-C Wu
Archana Monie
Cervical cancer is the second leading cause of cancer deaths in women worldwide and HPV infection is responsible for the development of this cancer. Effective vaccination against HPV represents an opportunity for the control of cervical can...